Jan van den Brand
Directeur/Membre du Conseil chez Nexins Research BV
Profil
Jan van den Brand is currently the Director at Nexins Research BV and the former General Manager at Amgen BV.
He previously worked as the Managing Director at MUbio Holding BV.
He holds an MBA from Erasmus University Rotterdam and a doctorate from the University Medical Center of Utrecht.
Postes actifs de Jan van den Brand
| Sociétés | Poste | Début |
|---|---|---|
Amgen BV
 Amgen BV Pharmaceuticals: MajorHealth Technology Part of Amgen, Inc., Amgen BV is a Dutch biotech company that specializes in using living cells to create biologic medicines. The company has helped pioneer the biotech industry and are committed to discovering, developing, manufacturing, and delivering innovative human therapeutics to patients suffering from serious illnesses. Amgen's medicines treat serious illnesses and typically address diseases with a limited number of treatment options. The company has a presence in approximately 100 countries and have reached millions of people with their products. Amgen has a robust pipeline focused on the pursuit of transformative medicines with large effects in serious diseases, using human genetic validation whenever possible to strengthen the evidence base for as many of their programs as possible. | Corporate Officer/Principal | 17/05/2010 |
| Nexins Research BV | Directeur/Membre du Conseil | 17/05/2010 |
Anciens postes connus de Jan van den Brand
| Sociétés | Poste | Fin |
|---|---|---|
MUbio Holding BV
 MUbio Holding BV BiotechnologyHealth Technology MUbio Products B.V. (MUbio) is a privately owned Dutch biotech company, founded in 2000 by Dr. R. Vleugels and Prof. Dr. F. Ramaekers. The company originated as a spin out from the Department of Molecular Cell Biology of the Maastricht University. MUbio produces high quality reagents and bioassays for cell biology and biomedical research. MUbio's product portfolio includes an increasing number of well-characterized antibodies for oncology research, produced in an ISO certified laboratory. MUbio’s partnered and proprietary R&D projects focus on the identification and validation of cancer biomarkers, development of lung cancer diagnostic kits & research and development of a lung cancer vaccine. | President | 05/06/2013 |
Formation de Jan van den Brand
| University Medical Center of Utrecht | Doctorate Degree |
| Erasmus University Rotterdam | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
MUbio Holding BV
MUbio Holding BV BiotechnologyHealth Technology MUbio Products B.V. (MUbio) is a privately owned Dutch biotech company, founded in 2000 by Dr. R. Vleugels and Prof. Dr. F. Ramaekers. The company originated as a spin out from the Department of Molecular Cell Biology of the Maastricht University. MUbio produces high quality reagents and bioassays for cell biology and biomedical research. MUbio's product portfolio includes an increasing number of well-characterized antibodies for oncology research, produced in an ISO certified laboratory. MUbio’s partnered and proprietary R&D projects focus on the identification and validation of cancer biomarkers, development of lung cancer diagnostic kits & research and development of a lung cancer vaccine. | Health Technology |
Amgen BV
Amgen BV Pharmaceuticals: MajorHealth Technology Part of Amgen, Inc., Amgen BV is a Dutch biotech company that specializes in using living cells to create biologic medicines. The company has helped pioneer the biotech industry and are committed to discovering, developing, manufacturing, and delivering innovative human therapeutics to patients suffering from serious illnesses. Amgen's medicines treat serious illnesses and typically address diseases with a limited number of treatment options. The company has a presence in approximately 100 countries and have reached millions of people with their products. Amgen has a robust pipeline focused on the pursuit of transformative medicines with large effects in serious diseases, using human genetic validation whenever possible to strengthen the evidence base for as many of their programs as possible. | Health Technology |
| Nexins Research BV |
